Correct Answer: C. Azithromycin
This clinical presentation—paroxysmal cough followed by apnea in a 3-week-old infant with markedly elevated TLC (>50,000 cells/μL)—is pathognomonic for pertussis (whooping cough) caused by Bordetella pertussis. The paroxysmal cough with post-tussive apnea is the hallmark of the paroxysmal stage. In infants <6 months, pertussis is particularly severe and life-threatening, with apnea being a cardinal feature. Azithromycin is the first-line macrolide antibiotic for pertussis in India and globally, as per IAP guidelines and WHO recommendations. It achieves excellent respiratory secretion penetration, eradicates the organism from the nasopharynx, and reduces disease transmission. The dose in infants is 10 mg/kg/day for 5 days. Macrolides are superior to beta-lactams because B. pertussis produces toxins (pertussis toxin, tracheal cytotoxin) that cause the characteristic cough; antibiotics primarily prevent secondary bacterial superinfection and reduce communicability rather than dramatically altering the cough course once established. Azithromycin is preferred over erythromycin due to better tolerability and lower incidence of hypertrophic pyloric stenosis in young infants. Early antibiotic therapy (within the catarrhal stage) is most effective; in the paroxysmal stage shown here, antibiotics mainly prevent transmission and complications.
Why the other options are wrong
A. Amoxicillin — Beta-lactams like amoxicillin are ineffective against pertussis because B. pertussis is inherently resistant to penicillins and cephalosporins. The organism's cell wall structure and lack of penicillin-binding protein affinity render beta-lactams useless. This is a classic NBE trap—students may default to amoxicillin as a 'first-line' antibiotic for respiratory infections, but pertussis requires macrolides specifically. B. Clarithromycin — While clarithromycin is a macrolide and theoretically active against B. pertussis, it is not preferred in infants <6 months due to increased risk of hypertrophic pyloric stenosis (HPS), particularly when used in the first 2 weeks of life. Azithromycin has a much lower HPS risk profile and is the macrolide of choice in neonates and young infants per IAP and international guidelines. D. Cotrimoxazole — Cotrimoxazole (trimethoprim-sulfamethoxazole) has *poor activity against B. pertussis*** and is not recommended for pertussis treatment. Additionally, sulfonamides are contraindicated in infants <6 weeks due to risk of kernicterus (displacement of bilirubin from albumin). This option represents both microbiological and pharmacological unsuitability in this age group.
High-Yield Facts
- Pertussis in infants <6 months: presents with paroxysmal cough, post-tussive apnea, and cyanosis; TLC typically >50,000 cells/μL with lymphocytic predominance.
- Azithromycin dosing in pertussis: 10 mg/kg/day for 5 days; preferred macrolide in infants due to lowest HPS risk.
- Macrolides vs. beta-lactams in pertussis: B. pertussis is intrinsically resistant to penicillins and cephalosporins; macrolides are the only effective oral antibiotics.
- Timing of antibiotic efficacy: most effective in catarrhal stage; in paroxysmal stage, antibiotics reduce transmission and prevent complications rather than shorten cough duration.
- Hypertrophic pyloric stenosis risk: clarithromycin and erythromycin carry higher HPS risk in infants <6 weeks; azithromycin is safer.
Mnemonics
PERTUSSIS MACROLIDE CHOICE: AZI-SAFE AZIthromycin is the SAFE choice in infants: Azithromycin (lowest HPS risk), Safest in neonates, Achieves good lung penetration, Fastest eradication of nasopharyngeal carriage. Use when you see 'infant + paroxysmal cough + high TLC'. BORDETELLA RESISTANCE: BETA-LACTAMS BLOCKED Bordetella is resistant to Beta-lactams (penicillins, cephalosporins). Remember: B-B = Blocked. Pertussis needs macrolides only.
NBE Trap
NBE pairs 'respiratory infection in infant' with 'amoxicillin' to trap students who default to beta-lactams without recognizing the specific pathogen (B. pertussis) and its intrinsic resistance pattern. The high TLC (>50,000) is the discriminating clue that this is pertussis, not a typical bacterial pneumonia.
Clinical Pearl
In Indian pediatric practice, pertussis remains a significant cause of infant morbidity and mortality, especially in unvaccinated or partially vaccinated populations. Early recognition by the characteristic paroxysmal cough with post-tussive apnea and marked lymphocytosis allows prompt azithromycin initiation, which reduces nasopharyngeal shedding and protects household contacts—critical in resource-limited settings where close family contact is common.
_Reference: OP Ghai (Pediatrics) Ch. 5 (Infectious Diseases); IAP Guidelines on Pertussis Management; Harrison Ch. 142 (Bordetella)_